TY - JOUR
T1 - Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions
T2 - Two-year outcomes in New York state
AU - Hannan, Edward L.
AU - Zhong, Ye
AU - Wu, Chuntao
AU - Walford, Gary
AU - Holmes, David R.
AU - Jacobs, Alice K.
AU - Stamato, Nicholas J.
AU - Venditti, Ferdinand J.
AU - Sharma, Samin
AU - Fergus, Icilma
AU - King, Spencer B.
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Objectives To compare 2-year outcomes (mortality, mortality/myocardial infarction (MI), target vessel PCI (TVPCI), and target lesion PCI (TLPCI)) for patients receiving EES and ZES. Background The utilization of drug-eluting coronary stents (DES) among patients undergoing percutaneous coronary interventions (PCI) has increased dramatically in the last decade. Everolimus-eluting stents (EES) and ENDEAVOR zotarolimus eluting stents (ZES) constitute the latest generation of approved DES in the United States, but little is known about their relative effectiveness. Methods New York patients undergoing EES and ZES revascularization without any other type of stent between 7/08 and 12/08 were propensity matched at the hospital level using multiple patient, operator, and hospital characteristics, and matched patients were followed through the end of 2010 to obtain comparative 2-year outcomes. Results A total of 3286 patients were propensity-matched. Patients receiving EES had a significantly lower TVPCI rate (9.0% vs. 11.9%, AHR = 1.31, 95% CI (1.04, 1.65)) and a significantly lower TLPCI rate (6.0% vs. 8.3%, AHR = 1.35, 95% CI (1.02, 1.79)). There was no significant difference between EES and ZES for mortality or MI/mortality. Conclusions There were no significant differences in the hard endpoints of death or MI between patients who received EES versus those who received ZES (ENDEAVOR). Patients with EES experienced lower repeat revascularization rates than patients with ZES at 24 months.
AB - Objectives To compare 2-year outcomes (mortality, mortality/myocardial infarction (MI), target vessel PCI (TVPCI), and target lesion PCI (TLPCI)) for patients receiving EES and ZES. Background The utilization of drug-eluting coronary stents (DES) among patients undergoing percutaneous coronary interventions (PCI) has increased dramatically in the last decade. Everolimus-eluting stents (EES) and ENDEAVOR zotarolimus eluting stents (ZES) constitute the latest generation of approved DES in the United States, but little is known about their relative effectiveness. Methods New York patients undergoing EES and ZES revascularization without any other type of stent between 7/08 and 12/08 were propensity matched at the hospital level using multiple patient, operator, and hospital characteristics, and matched patients were followed through the end of 2010 to obtain comparative 2-year outcomes. Results A total of 3286 patients were propensity-matched. Patients receiving EES had a significantly lower TVPCI rate (9.0% vs. 11.9%, AHR = 1.31, 95% CI (1.04, 1.65)) and a significantly lower TLPCI rate (6.0% vs. 8.3%, AHR = 1.35, 95% CI (1.02, 1.79)). There was no significant difference between EES and ZES for mortality or MI/mortality. Conclusions There were no significant differences in the hard endpoints of death or MI between patients who received EES versus those who received ZES (ENDEAVOR). Patients with EES experienced lower repeat revascularization rates than patients with ZES at 24 months.
KW - coronary angioplasty
KW - coronary stent outcomes
KW - drug-eluting stents
KW - percutaneous coronary interventions
UR - http://www.scopus.com/inward/record.url?scp=84878227688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878227688&partnerID=8YFLogxK
U2 - 10.1002/ccd.24512
DO - 10.1002/ccd.24512
M3 - Article
C2 - 22707353
AN - SCOPUS:84878227688
SN - 1522-1946
VL - 81
SP - 1097
EP - 1105
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 7
ER -